Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

By sjmartinez • May 4, 2025

Leboulleux S, Boucai L, Busaidy N, Durante C, Fagin JA, Fazeli S, Gianoukakis AG, Haugen BR, Kang H, Konda B, Laetsch TW, Locati L, Ryder M, Spitzweg C, Worden FP, Wirth L, Ho A. Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. Lancet Diabetes Endocrinol. 2025 Apr 30:S2213-8587(25)00064-6. doi: 10.1016/S2213-8587(25)00064-6. Epub ahead of print. PMID: 40318680.

Tags: Endocrinology, Harbor UCLA, Publications

Utility of prophylactic central dissection in papillary thyroid carcinoma with clinically apparent lymph node metastases isolated to the lateral neck

Ngo S, Hu TX, Zhu CY, Hughes EG, Mao YV, Yeh MW, Livhits MJ, Wu JX. Utility of prophylactic central dissection in papillary thyroid carcinoma[...]

Risk Factors for Thyroid Function Test Abnormalities During Pregnancy: A Systematic Review of the Literature to Validate Current Risk Factors and Identify Novel Ones

Liu Y, Osinga JAJ, Maraka S, Bliddal S, Alexander EK, Dosiou C, Boelaert K, Brenta G, Krabbendam E, Eaton JL, Guan H, Lee SY, Morris-Wiseman[...]

Loss of Ovarian Function Prevents Exercise-Induced Activation of Hepatic Mitophagic Flux

Franczak E, Kugler BA, Salathe SF, Allen J, Sardiu ME, McCoin CS, Hevener AL, Morris EM, Thyfault JP. Loss of Ovarian Function Prevents Exercise-Induced Activation[...]